Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...